Medical Biobanks Market To Reach $27.54bn In 2020, According To New Visiongain Data

06 September 2018
Pharma

A report published by visiongain forecasts the worldwide medical biobanking industry will achieve revenues of $27.54 billion in 2020. That sales prediction and others appear in Biobanking Market Forecasts 2016-2026: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells. In April 2016 that updated study appeared.

Visiongain is a business information publisher and consultancy in London, UK. Its purpose is to help organisations understand industries and markets in healthcare and other fields, especially their commercial prospects.

The biobanking market will expand its overall revenues at a CAGR of 9.5% between 2015 and 2026, the new study predicts. Biobanking holds high commercial potential, serving important needs in pharmaceutical research and development, as well as basic medical research. In 2015 biobanks for research purposes formed the most lucrative part of that industry, accounting for 77.1% of the overall world market. The study shows that segment will show strong revenue expansion from 2015 to 2026.

That report’s author said: “With the ever increasing need for novel therapies and the shift towards precision medicine, high quality biobanking samples are in great demand. To meet demand, those in the biobanking industry will have to move towards standardisation and harmonisation, as well as planning ahead towards long-term financial sustainability. Another important factor will be increasing public awareness to facilitate participation, as sample donation is critical to the success of biobanking.”

Visiongain’s updated investigation shows revenue forecasts to 2026 at world market, submarket and national level. It forecasts biobanking for research and for therapeutic uses in human medicine. It also forecasts the numbers of samples stored for those two uses.

That report predicts revenues to 2026 for the following subsectors of biobanking for research:

• Human tissues (further divided to commercial and public sectors)
• Stem cells
• Other biological samples (e.g. DNA, RNA, body fluids).

The study also predicts revenues to 2026 for the following segments of biobanking for therapeutic uses:

• Umbilical cord stem cell banking
• Adult stem cell banking.

Furthermore the work analyses 12 leading national markets for biobanking, providing revenue forecasts to 2026 for each:

• The US
• Japan
• Germany, France, the UK, Italy, Spain and the Netherlands
• Brazil, Russia, India and China.

Visiongain’s survey examines leading biorepositories and related companies. That work also discusses systems, software, consumables and services used by biobanks. That 248 page report gives 72 tables, 74 charts and two interviews with authorities in that field.

Biobanking Market Forecasts 2016-2026: Discover Prospects for Medical Research and Therapeutic Uses, Including Human Tissues, Fluids and Stem Cells adds to visiongain’s analytical portfolio on industries and markets in healthcare. Those reports cover pharmaceuticals, medical devices, diagnostics and outsourced services.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever